Search results
Results from the Tech24 Deals Content Network
Treatment with tirzepatide, the chemical name for Lilly's obesity drug Zepbound and diabetes treatment Mounjaro, resulted in an average weight reduction of 22.9%, compared to just 2.1% for the ...
Eli Lilly (NYSE: LLY), the developer of Mounjaro, has proven that it can compete with Novo Nordisk at a high level. Moreover, the company's sibling treatment to Mounjaro -- Zepbound -- has gotten ...
Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday.
FactSet says analysts expect Mounjaro and Zepbound to bring in more than $15 billion in combined sales this year. That combination could top $40 billion annually by the end of the decade. Shares of Indianapolis-based Eli Lilly and Co. jumped more than 9% to $845.42 Thursday afternoon. The Standard & Poor's 500 index rose more than 2%.
The synthesis of tirzepatide was first disclosed in patents filed by Eli Lilly and Company. [35] This uses standard solid phase peptide synthesis , with an allyloxycarbonyl protecting group on the lysine at position 20 of the linear chain of amino acids, allowing a final set of chemical transformations in which the sidechain amine of that ...
On Thursday, Eli Lilly And Co (NYSE:LLY) reported second-quarter revenue of $11.3 billion, up 36% year over year, easily surpassing the consensus of $9.95 billion. The increase was driven by a 27% ...
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union Army veteran of the American Civil War for whom the company was later named.
Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected.